Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Dollar change -0.69
Percentage change -2.19	%

Held by: IJR CALF VTI IWM VB VXF IJS VBK IWO PJP

Index	RUT	P/E	22.13	EPS (ttm)	1.39	Insider Own	2.28%	Shs Outstand	46.48M	Perf Week	4.76%
Market Cap	1.43B	Forward P/E	8.62	EPS next Y	3.58	Insider Trans	-10.11%	Shs Float	45.49M	Perf Month	18.08%
Income	70.47M	PEG	2.28	EPS next Q	0.68	Inst Own	108.04%	Short Float	7.92%	Perf Quarter	5.98%
Sales	681.75M	P/S	2.10	EPS this Y	-1.38%	Inst Trans	2.33%	Short Ratio	5.64	Perf Half Y	7.91%
Book/sh	19.18	P/B	1.61	EPS next Y	29.01%	ROA	4.54%	Short Interest	3.60M	Perf Year	-23.81%
Cash/sh	7.00	P/C	4.40	EPS next 5Y	9.70%	ROE	8.49%	52W Range	25.33 - 42.63	Perf YTD	-8.65%
Dividend Est.	-	P/FCF	8.28	EPS past 5Y	-	ROI	4.84%	52W High	-27.70%	Beta	0.89
Dividend TTM	-	Quick Ratio	4.78	Sales past 5Y	15.46%	Gross Margin	64.74%	52W Low	21.67%	ATR (14)	1.23
Dividend Ex-Date	-	Current Ratio	5.81	EPS Y/Y TTM	780.50%	Oper. Margin	13.70%	RSI (14)	62.81	Volatility	4.09% 3.91%
Employees	712	Debt/Eq	0.65	Sales Y/Y TTM	1.88%	Profit Margin	10.34%	Recom	1.20	Target Price	44.90
Option/Short	Yes / Yes	LT Debt/Eq	0.63	EPS Q/Q	145.11%	Payout	0.00%	Rel Volume	0.75	Prev Close	31.51
Sales Surprise	1.09%	EPS Surprise	-0.02%	Sales Q/Q	4.23%	Earnings	May 07 AMC	Avg Volume	639.15K	Price	30.82
SMA20	10.98%	SMA50	8.58%	SMA200	0.22%	Trades		Volume	478,755	Change	-2.19%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-07-24	Resumed	JP Morgan	Overweight	$80 → $45
Dec-20-23	Initiated	Raymond James	Outperform	$42
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform	$50
Jan-31-23	Resumed	Wedbush	Outperform	$88 → $60
Oct-21-22	Resumed	Jefferies	Buy	$66
Jan-03-22	Resumed	JP Morgan	Overweight	$75 → $83
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight	$75
Apr-21-21	Resumed	JP Morgan	Neutral	$70
Apr-09-21	Initiated	Berenberg	Buy	$93
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$86
Feb-11-21	Downgrade	Northland Capital	Outperform → Market Perform	$72 → $75
Jan-21-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$75
Sep-21-20	Upgrade	Northland Capital	Market Perform → Outperform	$58 → $67
Jul-06-20	Reiterated	Needham	Buy	$52 → $64
May-27-20	Initiated	Guggenheim	Neutral
Apr-07-20	Initiated	Northland Capital	Outperform	$50
Mar-20-20	Upgrade	SVB Leerink	Mkt Perform → Outperform	$44
Feb-24-20	Reiterated	H.C. Wainwright	Buy	$60 → $63
Jan-24-20	Initiated	SunTrust	Buy
Jan-23-20	Initiated	SunTrust	Buy

Show Previous Ratings

May-10-24 07:00AM	Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029 (GlobeNewswire)
May-08-24 04:05PM	Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes (GlobeNewswire) +11.84%
11:35AM	Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues (Zacks)
09:33AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:47AM	Pacira BioSciences Inc (PCRX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth ... (GuruFocus.com)
09:01PM	Loading…
May-07-24 09:01PM	PCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:03PM	Pacira BioSciences Reports Q1 2024 Results: Aligns with EPS Projections and Announces $150 ... (GuruFocus.com)
05:30PM	Here's What Key Metrics Tell Us About Pacira (PCRX) Q1 Earnings (Zacks)
04:13PM	Pacira: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program (GlobeNewswire)
08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
Apr-30-24 08:00AM	Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024 (GlobeNewswire)
Apr-04-24 11:33AM	Aggressive Stock Portfolio: 13 Stocks Picked by Analysts (Insider Monkey)
Apr-02-24 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-14-24 08:23AM	Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag (Zacks)
07:00AM	Loading…
Mar-13-24 07:00AM	Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee (GlobeNewswire)
Mar-08-24 11:55PM	Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc (PCRX) (GuruFocus.com)
Mar-06-24 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference (GlobeNewswire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Mar-01-24 08:38AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:05AM	Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues (Zacks)
12:28AM	Q4 2023 Pacira Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-29-24 10:00AM	Here's What Key Metrics Tell Us About Pacira (PCRX) Q4 Earnings (Zacks)
09:15AM	Pacira (PCRX) Matches Q4 Earnings Estimates (Zacks)
08:32AM	Pacira BioSciences Inc (PCRX) Reports Record Revenues and Robust Earnings for Full-Year 2023 (GuruFocus.com)
08:26AM	Pacira: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-22-24 08:00AM	Pacira to Report 2023 Financial Results on Thursday February 29, 2024 (GlobeNewswire)
Feb-15-24 08:36AM	Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy (GlobeNewswire)
Feb-07-24 08:00AM	Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc. (GlobeNewswire) -7.44%
10:45AM	Loading…
Feb-01-24 10:45AM	G.O.A.T. Bowl I Registration Open to 4 Additional Pickleball Teams (PR Newswire)
Jan-05-24 12:21PM	Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong (Zacks) +5.71%
Jan-04-24 05:00PM	Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues (GlobeNewswire)
Jan-03-24 08:00AM	Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-23 07:30AM	Pacira Appoints Frank D. Lee as Chief Executive Officer (GlobeNewswire)
Dec-06-23 11:13AM	Hedge Funds are Betting on These 14 Sliding Stocks (Insider Monkey)
Nov-13-23 10:10AM	Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion (Zacks)
Nov-10-23 07:30AM	Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications (GlobeNewswire)
Nov-07-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November (GlobeNewswire)
Nov-04-23 10:28AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 12:34PM	Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated (Zacks)
10:00AM	Pacira BioSciences Inc (PCRX) Reports Q3 2023 Financial Results (GuruFocus.com)
08:23AM	Pacira: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Pacira BioSciences Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-26-23 08:00AM	Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023 (GlobeNewswire)
Oct-12-23 08:00AM	American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc. (GlobeNewswire)
Oct-10-23 08:00AM	Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors (GlobeNewswire)
Oct-02-23 08:00AM	American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient Care (GlobeNewswire)
Sep-27-23 12:07PM	Unraveling the Future of Pacira BioSciences Inc (PCRX): A Deep Dive into Key Metrics (GuruFocus.com) -6.51%
11:50AM	Unveiling Pacira BioSciences (PCRX)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
Sep-26-23 04:30PM	Pacira BioSciences Announces Leadership Succession Plan (GlobeNewswire)
Sep-06-23 08:00AM	Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 10:03AM	Qualcomm downgraded, Wingstop upgraded: Wall Street's top analyst calls (The Fly) +5.56%
Aug-02-23 12:45PM	Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated (Zacks)
08:11AM	Pacira: Q2 Earnings Snapshot (AP Finance)
08:00AM	Pacira BioSciences Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey)
Jul-26-23 08:00AM	Pacira to Report Second Quarter 2023 Financial Results on Wednesday August 2, 2023 (GlobeNewswire)
Jun-21-23 08:00PM	PCRX: Raising target price to $42.00 (Argus Research)
Jun-02-23 11:31AM	Why Is Pacira (PCRX) Down 11.8% Since Last Earnings Report? (Zacks)
May-31-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-09-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-03-23 11:42PM	Q1 2023 Pacira Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -7.17%
05:25PM	Why Pacira BioSciences Shares Are Trading Lower Today (Benzinga)
03:11PM	Pacira (PCRX) Q1 Earnings Miss Estimates, Revenues Beat (Zacks)
08:11AM	Pacira: Q1 Earnings Snapshot (AP Finance)
08:00AM	Pacira BioSciences Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-26-23 08:00PM	PCRX: Lowering target price to $35.00 (Argus Research)
08:00AM	Pacira to Report First Quarter 2023 Financial Results on Wednesday May 3, 2023 (GlobeNewswire)
Apr-20-23 09:20AM	A Look At The Fair Value Of Pacira BioSciences, Inc. (NASDAQ:PCRX) (Simply Wall St.)
08:00AM	Pacira BioSciences Partners with The Invited Celebrity Classic a PGA TOUR Champions Event to Make iovera° The Official Non-Opioid Pain Management Partner (GlobeNewswire)
Apr-19-23 08:00AM	Pacira BioSciences, Inc. Appoints Christopher Young as Chief Manufacturing Officer (GlobeNewswire)
Apr-12-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-03-23 08:00AM	Pacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using Proceeds from New $150 Million 5-Year Term Loan A Facility and Existing Cash Resources (GlobeNewswire)
Mar-30-23 11:30AM	Why Is Pacira (PCRX) Down 6% Since Last Earnings Report? (Zacks)
Mar-29-23 08:00AM	Pacira Announces FDA Acceptance of sNDA for Exparel Nerve Blocks to Produce Regional Analgesia in Lower Extremity Procedures (GlobeNewswire)
Mar-27-23 08:00AM	Third Circuit Court Upholds Decision to Dismiss Pacira BioSciences, Inc. Lawsuit (GlobeNewswire)
Mar-24-23 08:50AM	Pacira BioSciences (NASDAQ:PCRX) shareholders have lost 49% over 1 year, earnings decline likely the culprit (Simply Wall St.)
Mar-22-23 08:00AM	Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors (GlobeNewswire)
Mar-09-23 09:17AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-08-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference (GlobeNewswire)
Feb-28-23 11:39PM	Q4 2022 Pacira Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
08:00AM	Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results (GlobeNewswire)
Feb-23-23 08:00AM	LPGA, Pacira BioSciences Partner to Raise Awareness of Non-Opioid Pain Management Solutions (GlobeNewswire)
Feb-21-23 08:00AM	Pacira to Report 2022 Financial Results on Tuesday February 28, 2023 (GlobeNewswire)
Jan-05-23 04:30PM	Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million (GlobeNewswire)
Jan-04-23 08:00AM	Pacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-22 10:06AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? (Simply Wall St.)
Dec-13-22 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $57.5 Million for November 2022 (GlobeNewswire) -6.64%
Nov-18-22 01:38PM	Will Pacira's (PCRX) Exparel Aid Growth Amid High Reliance? (Zacks)
Nov-17-22 08:05AM	New Research Reveals Common Treatments for Knee Pain are Falling Short, Placing Physical, Social, and Mental Burden on Patients (PR Newswire)
Nov-14-22 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022 (GlobeNewswire)
Nov-09-22 05:14AM	Pacira BioSciences Third Quarter 2022 Earnings: EPS Misses Expectations (Simply Wall St.)
Nov-08-22 08:00AM	Pacira BioSciences to Present at Two Healthcare Conferences in November (GlobeNewswire)
Nov-04-22 10:54AM	Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat (Zacks)
Nov-03-22 09:15AM	Pacira (PCRX) Lags Q3 Earnings Estimates (Zacks)
08:00AM	Pacira BioSciences Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-01-22 10:01AM	VAXART, INC. (VXRT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-27-22 10:02AM	Pacira (PCRX) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-20-22 08:00AM	Pacira to Report Third Quarter 2022 Financial Results on Thursday November 3, 2022 (GlobeNewswire)

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PACE GARY W	Director	Mar 08 '24	Sale	30.60	90,000	2,754,000	22,127	Mar 08 05:33 PM
PACE GARY W	Director	Mar 07 '24	Sale	30.81	28,257	870,598	112,127	Mar 08 05:33 PM
PACE GARY W	Director	Mar 06 '24	Sale	29.67	1,066	31,628	140,384	Mar 08 05:33 PM
WINSTON ROY	Chief Medical Officer	Aug 02 '23	Sale	34.88	509	17,751	52,440	Aug 04 04:47 PM
Riker Lauren Bullaro	Senior Vice President, Finance	Jul 05 '23	Sale	38.91	643	25,019	22,687	Jul 07 08:04 PM
Riker Lauren Bullaro	Senior Vice President, Finance	Jun 14 '23	Sale	38.42	6,366	244,606	22,687	Jun 16 05:39 PM
Williams Kristen Marie	Chief Administrative Officer	Jun 14 '23	Sale	37.03	6,467	239,473	25,375	Jun 16 05:42 PM
Kronenfeld Mark A.	Director	Jun 08 '23	Option Exercise	29.90	15,000	448,500	32,897	Jun 12 04:16 PM
Kronenfeld Mark A.	Director	Jun 08 '23	Sale	37.04	15,000	555,600	17,897	Jun 12 04:16 PM
STACK DAVID M	CEO and Chairman	Jun 07 '23	Sale	37.87	5,326	201,669	153,781	Jun 07 09:33 PM
WINSTON ROY	Chief Medical Officer	Jun 07 '23	Sale	37.87	1,857	70,315	41,356	Jun 07 09:36 PM
Reinhart Charles A. III	Chief Financial Officer	Jun 07 '23	Sale	37.87	1,371	51,913	33,626	Jun 07 09:29 PM
Williams Kristen Marie	Chief Administrative Officer	Jun 07 '23	Sale	37.87	1,357	51,383	20,892	Jun 07 09:34 PM
Ellis Ronald J. Jr.	Chief Strategy Officer	Jun 07 '23	Sale	37.87	1,162	43,999	30,909	Jun 07 09:20 PM
REINHARDT MAX	President, Rest of World	Jun 07 '23	Sale	37.87	1,099	41,614	29,225	Jun 07 09:28 PM
McLoughlin Dennis	Chief Customer Officer	Jun 07 '23	Sale	37.87	1,057	40,023	38,115	Jun 07 09:24 PM
GAUGLER DARYL	Chief Operating Officer	Jun 07 '23	Sale	37.87	1,047	39,645	21,539	Jun 07 09:22 PM
Riker Lauren Bullaro	Senior Vice President, Finance	Jun 07 '23	Sale	37.87	616	23,325	19,053	Jun 07 09:31 PM
SLONIN JONATHAN	Chief Clinical Officer	Jun 07 '23	Sale	37.87	490	18,554	36,323	Jun 07 09:32 PM
STACK DAVID M	CEO and Chairman	Jun 06 '23	Sale	38.99	5,058	197,216	159,107	Jun 07 09:33 PM
MOLLOY ANTHONY	Chief Lgl & Compliance Officer	Jun 06 '23	Sale	38.55	4,521	174,285	12,877	Jun 07 09:26 PM
WINSTON ROY	Chief Medical Officer	Jun 06 '23	Sale	38.99	1,779	69,365	43,213	Jun 07 09:36 PM
Williams Kristen Marie	Chief Administrative Officer	Jun 06 '23	Sale	38.99	1,301	50,727	22,249	Jun 07 09:34 PM
Reinhart Charles A. III	Chief Financial Officer	Jun 06 '23	Sale	38.99	1,236	48,193	34,997	Jun 07 09:29 PM
Ellis Ronald J. Jr.	Chief Strategy Officer	Jun 06 '23	Sale	38.99	1,114	43,436	32,071	Jun 07 09:20 PM
REINHARDT MAX	President, Rest of World	Jun 06 '23	Sale	38.99	1,054	41,097	30,324	Jun 07 09:28 PM
McLoughlin Dennis	Chief Customer Officer	Jun 06 '23	Sale	38.99	1,014	39,537	39,172	Jun 07 09:24 PM
GAUGLER DARYL	Chief Operating Officer	Jun 06 '23	Sale	38.99	1,005	39,186	22,586	Jun 07 09:22 PM
Riker Lauren Bullaro	Senior Vice President, Finance	Jun 06 '23	Sale	38.99	591	23,044	19,669	Jun 07 09:31 PM
SLONIN JONATHAN	Chief Clinical Officer	Jun 06 '23	Sale	38.99	471	18,365	36,813	Jun 07 09:32 PM
MOLLOY ANTHONY	Chief Lgl & Compliance Officer	Jun 05 '23	Sale	38.28	2,267	86,774	17,398	Jun 07 09:26 PM
GAUGLER DARYL	Chief Operating Officer	Jun 05 '23	Sale	38.74	1,000	38,740	23,591	Jun 07 09:22 PM
Brege Laura	Director	Jun 05 '23	Sale	38.74	600	23,244	9,547	Jun 07 09:18 PM
HASTINGS PAUL J	Director	Jun 05 '23	Sale	38.34	580	22,237	6,599	Jun 07 09:23 PM
GAUGLER DARYL	Chief Operating Officer	May 31 '23	Option Exercise	34.00	2,500	85,000	26,894	Jun 02 06:28 PM
GAUGLER DARYL	Chief Operating Officer	May 31 '23	Sale	39.08	2,500	97,700	24,591	Jun 02 06:28 PM

Open in Screener

CRDF

Cardiff Oncology Inc

May 17 • 04:00PM ET

3.63

Dollar change -0.11
Percentage change -2.94	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC AVSC

Index	-	P/E	-	EPS (ttm)	-0.90	Insider Own	8.10%	Shs Outstand	44.68M	Perf Week	7.08%
Market Cap	162.33M	Forward P/E	-	EPS next Y	-1.06	Insider Trans	0.84%	Shs Float	41.10M	Perf Month	-16.93%
Income	-40.25M	PEG	-	EPS next Q	-0.25	Inst Own	19.03%	Short Float	10.75%	Perf Quarter	109.83%
Sales	0.61M	P/S	266.12	EPS this Y	-5.11%	Inst Trans	-10.88%	Short Ratio	2.20	Perf Half Y	200.00%
Book/sh	1.36	P/B	2.67	EPS next Y	-8.44%	ROA	-44.55%	Short Interest	4.42M	Perf Year	105.08%
Cash/sh	1.50	P/C	2.42	EPS next 5Y	-	ROE	-51.12%	52W Range	0.94 - 6.42	Perf YTD	145.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	35.42%	ROI	-64.72%	52W High	-43.46%	Beta	1.90
Dividend TTM	-	Quick Ratio	5.91	Sales past 5Y	9.26%	Gross Margin	32.79%	52W Low	286.17%	ATR (14)	0.40
Dividend Ex-Date	-	Current Ratio	5.91	EPS Y/Y TTM	-1.77%	Oper. Margin	-7261.15%	RSI (14)	42.24	Volatility	7.03% 9.72%
Employees	32	Debt/Eq	0.03	Sales Y/Y TTM	54.43%	Profit Margin	-6598.85%	Recom	1.00	Target Price	10.50
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	10.78%	Payout	-	Rel Volume	0.27	Prev Close	3.74
Sales Surprise	228.00%	EPS Surprise	11.47%	Sales Q/Q	146.99%	Earnings	May 02 AMC	Avg Volume	2.01M	Price	3.63
SMA20	-6.06%	SMA50	-22.12%	SMA200	55.85%	Trades		Volume	539,195	Change	-2.94%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-22	Initiated	William Blair	Outperform
Dec-08-21	Initiated	Robert W. Baird	Outperform	$19
Aug-09-21	Resumed	Maxim Group	Buy	$30 → $20
Oct-22-20	Initiated	H.C. Wainwright	Buy	$27
Oct-08-20	Initiated	Piper Sandler	Overweight	$25

May-13-24 04:05PM	Cardiff Oncology to Present at Upcoming Investor Conferences in May (GlobeNewswire)
May-09-24 12:15PM	Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036 (PR Newswire) +5.62%
May-07-24 06:00AM	The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028 (InvestorPlace)
May-02-24 09:54PM	CRDF Stock Earnings: Cardiff Oncology Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.91%
05:45PM	Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update (GlobeNewswire)
Apr-25-24 04:05PM	Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update (GlobeNewswire)
Apr-08-24 04:05PM	Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study (GlobeNewswire)
Apr-01-24 08:50AM	Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) +7.30%
Mar-21-24 07:55AM	Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why (Zacks)
Mar-14-24 08:50AM	Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going (Zacks)
08:08AM	Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last? (Zacks)
Mar-06-24 04:05PM	Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024 (GlobeNewswire) +6.58%
12:00PM	What Makes Cardiff Oncology (CRDF) a Strong Momentum Stock: Buy Now? (Zacks)
Mar-01-24 10:12AM	Cardiff Oncology Inc (CRDF) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com) +64.87%
07:40PM	Loading…
Feb-29-24 07:40PM	Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update (GlobeNewswire)
04:06PM	Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC (GlobeNewswire)
04:05PM	Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004) (GlobeNewswire)
Feb-26-24 08:00AM	Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-22-24 08:00AM	Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update (GlobeNewswire)
Jan-17-24 10:30AM	Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research (PR Newswire) -9.82%
Nov-20-23 04:05PM	Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference (PR Newswire)
Nov-02-23 04:05PM	Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update (PR Newswire) +8.57%
Oct-26-23 04:05PM	Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update (PR Newswire)
Oct-23-23 08:45AM	Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing (PR Newswire) -10.27%
Oct-11-23 09:35AM	Cardiff Oncology (CRDF) Loses -29.75% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-26-23 04:05PM	Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy (PR Newswire)
Sep-05-23 08:00AM	Cardiff Oncology to Present at Upcoming Investor Conferences in September (PR Newswire)
Aug-09-23 04:05PM	Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update (PR Newswire) -12.39%
04:05PM	Loading…
Aug-07-23 04:05PM	Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship (PR Newswire) -8.19%
Jul-24-23 05:09PM	Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-20-23 05:22PM	Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-05-23 08:00AM	Cardiff Oncology to Present at the Jefferies Healthcare Conference (PR Newswire)
May-04-23 04:10PM	Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update (PR Newswire)
Mar-28-23 08:00AM	Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer (PR Newswire)
Mar-06-23 08:15AM	Cardiff Oncology Formally Introduces Scientific Advisory Board (PR Newswire)
Mar-04-23 07:11AM	Cardiff Oncology Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-02-23 04:10PM	Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update (PR Newswire)
Feb-27-23 08:15AM	Cardiff Oncology to Present at the Cowen 43rd Annual Health Care Conference (PR Newswire)
Feb-02-23 08:00AM	Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer (PR Newswire)
Jan-10-23 08:00AM	Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology Conference (PR Newswire)
Nov-21-22 10:52AM	Cardiff Oncology to Present at Upcoming Investor Conferences (PR Newswire)
Nov-08-22 08:15AM	Cardiff Oncology to Present at the Jefferies London Healthcare Conference (PR Newswire)
Nov-03-22 04:10PM	Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates (PR Newswire)
Sep-12-22 04:05PM	Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates (PR Newswire) +10.69%
Sep-10-22 07:30AM	Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022 (PR Newswire)
Sep-08-22 08:15AM	Cardiff Oncology to Present at Upcoming Investor Conferences in September (PR Newswire)
Sep-06-22 08:00AM	Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022 (PR Newswire) -9.25%
Aug-29-22 08:00AM	Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022 (PR Newswire) -5.73%
Aug-04-22 04:10PM	Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates (PR Newswire) +10.00%
Jul-05-22 08:30AM	Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022 (PR Newswire) +13.73%
Jul-02-22 09:10AM	Is Cardiff Oncology, Inc. (NASDAQ:CRDF) Popular Amongst Institutions? (Simply Wall St.)
May-17-22 08:30AM	Cardiff Oncology to Present at the H.C. Wainwright Global Investment Conference (PR Newswire) +6.06%
May-09-22 08:02AM	Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation (Simply Wall St.) -6.06%
May-05-22 04:10PM	Cardiff Oncology Reports First Quarter 2022 Results and Provides Business Updates (PR Newswire) -6.29%
Apr-12-22 04:00PM	Cardiff Oncology Announces Departure of Chief Medical Officer (PR Newswire)
Apr-08-22 01:05PM	Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting (PR Newswire)
01:05PM	Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer Models (PR Newswire)
Mar-22-22 09:05AM	Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC (PR Newswire) +7.56%
Mar-17-22 06:32AM	Cardiff Oncology, Inc. (NASDAQ:CRDF) insiders placed bullish bets worth US$681k in the last 12 months (Simply Wall St.) +6.48%
Mar-08-22 04:45PM	Cardiff Oncology Announces Upcoming Poster Presentations at the AACR Annual Meeting (PR Newswire)
Mar-01-22 08:30AM	Cardiff Oncology to Participate in Cowen's 42nd Annual Healthcare Conference (PR Newswire)
Feb-24-22 04:10PM	Cardiff Oncology Reports Fourth Quarter and Full Year 2021 Results and Recent Highlights (PR Newswire)
Feb-17-22 03:02PM	Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks) -5.79%
Jan-31-22 06:22PM	Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +6.96%
Jan-20-22 03:44PM	Dont Say Bye Bye to Cardiff Stock, Say Buy Buy: Analyst (TipRanks) -14.95%
01:46PM	Cardiff Oncology to Present at the B. Riley Securities 2022 Oncology Conference (PR Newswire)
Jan-18-22 05:00PM	Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival (PR Newswire) -10.50%
Jan-13-22 09:17AM	Are Institutions Heavily Invested In Cardiff Oncology, Inc.'s (NASDAQ:CRDF) Shares? (Simply Wall St.)
Jan-11-22 08:00AM	Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs (PR Newswire) +10.18%
Jan-10-22 08:00AM	Cardiff Oncology to Host Conference Call and Webcast to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Being Presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (PR Newswire)
Jan-04-22 08:00AM	Cardiff Oncology to Present at the H.C. Wainwright BioConnect Virtual Conference (PR Newswire)
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-21-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-16-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-10-21 08:30AM	Cardiff Oncology Announces Upcoming Presentation on Lead KRAS-mutated Metastatic Colorectal Cancer Program at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (PR Newswire)
Dec-08-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com) +11.07%
Dec-03-21 08:30AM	Cardiff Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-18-21 07:00AM	Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative (PR Newswire) +18.74%
Nov-14-21 07:18AM	Cardiff Oncology (NASDAQ:CRDF) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Nov-09-21 08:30AM	Cardiff Oncology to Present at Upcoming Jefferies London Healthcare and Piper Sandler 33rd Annual Investor Conferences (PR Newswire)
Nov-04-21 04:15PM	Cardiff Oncology Reports Third Quarter 2021 Results and Provides Business Updates (PR Newswire)
Oct-28-21 03:06PM	Will Cardiff Oncology (CRDF) Report Negative Q3 Earnings? What You Should Know (Zacks)
Sep-30-21 08:36PM	Insider Buying Could Indicate a Bottom in These 2 Stocks (TipRanks)
Sep-15-21 06:37AM	James Levine Is The Chief Financial Officer of Cardiff Oncology, Inc. (NASDAQ:CRDF) And Just Spent US$194k On Shares (Simply Wall St.)
Sep-08-21 04:00PM	Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival (PR Newswire)
Sep-07-21 08:30AM	Cardiff Oncology to Present at Upcoming Investor Conferences in September (PR Newswire)
Aug-25-21 08:15AM	Cardiff Oncology to Present New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer on September 8, 2021 (PR Newswire) +9.18%
Aug-06-21 04:15AM	How Many Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Do Institutions Own? (Simply Wall St.) +11.84%
Aug-05-21 04:15PM	Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business Updates (PR Newswire)
Aug-03-21 03:01PM	Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks) -5.51%
Jul-12-21 08:00AM	Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer (PR Newswire)
Jul-06-21 08:30AM	Cardiff Oncology to Participate in a Fireside Chat at the William Blair Biotech Focus Conference 2021 (PR Newswire)
Jun-28-21 08:30AM	Cardiff Oncology Added to the Russell 2000® and other FTSE Russell Indexes (PR Newswire)
Jun-10-21 12:30PM	Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors (PR Newswire)
Jun-08-21 08:30AM	Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer (PR Newswire)
May-24-21 08:35AM	Are Options Traders Betting on a Big Move in Cardiff Oncology (CRDF) Stock? (Zacks)
02:09AM	We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely (Simply Wall St.)
May-20-21 08:30AM	Cardiff Oncology to Present at the Jefferies Virtual Healthcare Conference (PR Newswire)

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PACE GARY W	Director	Dec 19 '23	Buy	1.37	30,000	41,100	697,761	Dec 19 06:39 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

PCRX

Pacira BioSciences Inc

CRDF

Cardiff Oncology Inc

Upgrade your FINVIZ experience